BL-22 / AstraZeneca - LARVOL DELTA

Moxetumomab Pasudotox: First Global Approval. (PubMed, Drugs) - "The product, discovered at the National Cancer Institute, is an optimised version of immunotoxin CAT-3888. This article summarizes the milestones in the development of moxetumomab pasudotox leading to this first approval for the treatment of adults with relapsed or refractory hairy cell leukaemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analogue. Development of moxetumomab pasudotox for non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and precursor cell lymphoblastic leukaemia/lymphoma was discontinued."

Clinical • Journal